On July 12, 2022, NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, announced the completion of $7.85 million seed funding round. Grantham Foundation and RA Capital Management led the financing with additional participation from Breakout Labs/Thiel Foundation, Thrive SVG Ventures, MARSBIO, and the United Mitochondrial Disease Foundation. Wilson Sonsini Goodrich & Rosati advised NAPIGEN on the transaction.

NAPIGEN will use the investment to apply its mitochondrial gene editing technology for hybrid seed production in wheat and rice.

The Wilson Sonsini team that advised NAPIGEN on the transaction includes:

Corporate
Mark Solakian
Priyanka Nawathe
Rozman Lynch

Patents and Innovations
Lora Green
Angel Wang

For more information, please see NAPIGEN's news release.